Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial
Launched by FRED HUTCHINSON CANCER CENTER · Oct 11, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MIND Trial is a study designed to see how a special online program can help improve the eating habits of women who have survived stage I-III breast cancer. Many breast cancer survivors struggle to meet the recommended nutrition guidelines, even though we know that healthy eating can help with recovery and overall health. The MIND program, delivered through the Cook for Your Life website, offers free resources like recipes and cooking videos to help make healthy eating easier and more enjoyable. By participating in this program, survivors may learn to eat more fruits and vegetables, which can positively impact their health.
To take part in the trial, you need to be at least 18 years old and have been diagnosed with stage I-III breast cancer within the last five years. You should be finished with any chemotherapy or radiation treatments for at least 60 days, be able to access the internet, and be willing to complete some online surveys and activities. It's also important that you don't currently smoke and typically eat fewer than five servings of fruits and vegetables a day. If you meet these requirements and are interested in improving your diet after cancer treatment, this program might be a great fit for you!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older.
- • Previous diagnosis of stage I-III breast cancer in the past 5 years at the time of enrollment.
- • No evidence of current, recurrent or metastatic disease.
- • At least 60 days post final chemotherapy, biologic therapy, or radiation therapy and/or surgery. The following which are allowed: HER2-targeted therapies, CDK4/6 inhibitor (abemaciclib or ribociclib), endocrine therapy (aromatase inhibitors, ovarian suppression therapy, and tamoxifen), PARP inhibitors (olaparib), and zolendronic acid.
- • Access to phone for study contacts.
- • Access to smartphone, tablet, or computer and internet to attend online program.
- • Willing and able to complete all study activities after randomization, including completing surveys online, at-home, and over the telephone assessments.
- • Able to understand and willing to sign written informed electronic (e) consent in English
- • Eastern Cooperative Oncology Group (ECOG) status of 0-2.
- • Participants must not be actively smoking within the past 30 days. Active smoking is defined as any smoking, even a puff. Participants who smoke are much less likely to engage in healthy lifestyle behaviors, and it is probably more important for participants to stop smoking than it is to change their dietary patterns. If identified as actively smoking, the individual will be referred to the local resources, Washington State Quitline (1-800-QUIT-NOW), ICanQuit.org, Quit2Heal.org, the national resource, Centers for Disease Control and Prevention (CDC) "Quit Now" phone line which supports smoking cessation, or the NIH quit support website "SmokeFree.gov.
- • Participants must consume \< 5 servings of fruits and vegetables per day as assessed by a brief questionnaire.
- • Physician approval to participate in the MIND program dietary intervention.
- • At the time of enrollment, women must not be pregnant or lactating or planning to become pregnant in the next 6 months.
About Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center is a leading nonprofit research institution dedicated to the pursuit of innovative cancer treatments and prevention strategies. Established in Seattle, Washington, the center is renowned for its pioneering work in hematopoietic cell transplantation and its commitment to advancing cancer research through collaborative clinical trials. By integrating cutting-edge science with compassionate patient care, Fred Hutchinson Cancer Center aims to improve outcomes for patients while fostering a multidisciplinary approach to tackling complex cancer challenges. With a strong emphasis on translating research findings into clinical applications, the center is at the forefront of developing novel therapies that offer hope to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Heather Greenlee
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported